On July 31st at 10:10 AM, IVD MEDICAL (01931) stock price surged to HK$4.99, registering a single-day gain of 15.78%. From the opening price of HK$2.22 per share on July 2nd to the closing price of HK$4.84 per share on July 31st, the stock achieved a remarkable 118% increase. The market frenzy stems from this company's series of strategic moves over the past half month — from announcing its dual primary listing in the US on July 14th to unveiling a new brand logo on July 30th, seven major strategic actions propelled the market capitalization from HK$3.6 billion to nearly HK$8 billion like rocket boosters.

IVD MEDICAL's July 31st stock performance chart

Through the cross-sector combination of "stablecoin + medical RWA," IVD MEDICAL has positioned itself as a "new species" in the capital markets.

**I. Lightning Seven-Strike Combo: A Medical Company's "Digital Transformation"**

IVD MEDICAL's July schedule was breathtakingly intense.

- July 14th: Announced the launch of NASDAQ dual primary listing plan, targeting expansion of international shareholder base. - Just three days later, unveiled an even more disruptive strategy: the world's first medical innovation drug RWA trading exchange ecosystem IVDNewCo Exchange and supporting stablecoin IVDDollar (IVDD) emerged. - July 20th: New York wholly-owned subsidiary IVD GROUP INC. was established, simultaneously submitting stablecoin license applications to SEC and CFTC. - July 23rd to 28th: The company executed three high-level share buybacks, spending over HK$6.13 million to repurchase 1.721 million shares, with average transaction prices climbing from HK$3.16 to HK$3.67. - July 29th: Subsidiary Wisdom secured a hundreds-of-millions yuan revolving loan led by Bank of East Asia, demonstrating financial institutions' endorsement of the company's development. - July 30th: Brand strategy upgrade — logo refreshed to "four checkmark ✓" symbols, brand essence reconstructed as the trinity of "Innovation-Validation-Development." - Same day: Established the Innovation Drug Intellectual Property Tokenization Fund (IVD-BGI CoWin) with BGI CoWin under BGI Genomics, bridging the last mile for medical asset blockchain integration.

IVD MEDICAL July 30th announcement

From capital operations to technical infrastructure, from brand reshaping to ecosystem alliances, IVD MEDICAL completed a transformation from IVD distributor to "medical innovation drug blockchain investment bank" within 18 days.

**II. Four Tailwinds Propelling Medical RWA**

IVD MEDICAL's cross-sector gamble coincides with historic industry opportunities.

The innovation drug sector is experiencing value revaluation. Among the 93 new drugs approved by regulators in 2024, 48 were Class 1 innovative drugs, with License-out transaction volumes soaring to $51.9 billion. The upfront payment of $1.25 billion for the PD-1/VEGF bispecific antibody licensing agreement between 3SBio and Pfizer confirms Chinese innovative drugs entering the global arena.

Capital markets have rekindled enthusiasm for innovation drugs. As of July 29th, the CSI Hong Kong Stock Connect Innovation Drug Index gained over 124% from its year-to-date low, with 16 innovation drug funds doubling returns. The E Fund Hong Kong Advantage Selection Fund, heavily weighted in this sector, achieved 139% returns, while innovation drug ETFs grew by 31.5 billion yuan. Capital is voting for the innovation drug track with real money.

Global stablecoin regulation is breaking new ground. On July 18th, the US "GENIUS Act" was signed into effect, requiring 100% reserve asset backing for stablecoins. Hong Kong's "Stablecoin Ordinance" took effect on August 1st, establishing a HK$25 million capital threshold. The EU's MiCA regulation is already effective in 30 countries, forming a compliance network spanning Europe, America, and Asia.

Blockchain technology is penetrating industry barriers. Ant Digital's new energy RWA project with Longshine completed 100 million yuan fundraising, validating the feasibility of real asset tokenization.

**III. Capital Revaluation: The Pricing Revolution Behind HK$8 Billion Market Cap**

The market is redefining this company with stunning gains. After launching dual listing on July 14th, IVD MEDICAL's stock price began rocket-like ascension. It surged 20.41% on July 18th, soared over 50% in early trading on July 21st, with cumulative gains from July 14th to 21st reaching 75.1%.

On July 31st, the company's stock price continued its meteoric rise, with intraday gains reaching 15.78%, touching the highest price of HK$4.99 per share, pushing market cap toward HK$8 billion. This represents investors' enthusiastic embrace of the "medical RWA + stablecoin" narrative.

Capital logic has been reconstructed. Traditional IVD distribution business carries approximately 23% gross margins, while Circle's stablecoin USDC contributes 99% of revenue, with market cap once exceeding $50 billion. IVD MEDICAL's valuation anchor is shifting from IVD leader distributor's price-to-sales ratio toward medical RWA exchange's ecosystem premium.

When IVD MEDICAL switches its identity to "global medical innovation value chain - decentralized science ecosystem builder," capital sees more compelling imagination space.

**IV. Pioneer Landscape: Passport to Trillion-Dollar Market**

IVD MEDICAL's surge is not isolated in the collision between Web3 and traditional finance. Circle, the first stablecoin stock, saw its share price soar from the $31 IPO price to a peak of $299 within 12 trading days after listing on NYSE. Guotai Junan International's stock price exploded 198.39% in a single day after receiving approval from Hong Kong's SFC to upgrade its virtual asset trading license. The market's thirst for compliant crypto assets is evident.

Boston Consulting predicts the global RWA market will reach $16.1 trillion by 2030. ARK Invest data shows 2024 stablecoin transfer volumes totaled $15.6 trillion, surpassing Visa for the first time. Medical innovation drug RWA, IVD MEDICAL's focus, represents the most professionally barriers-protected area in this blue ocean.

IVD MEDICAL's ambition lies in closed-loop ecosystem. The front-end captures innovation drug pipelines through the BGI CoWin fund, the middle-end realizes RWA tokenization on IVDNewCo Exchange, and the back-end completes payment and settlement using IVDD stablecoin. While traditional pharmaceutical companies still struggle with financing, IVD MEDICAL has constructed a capital highway "from laboratory to blockchain."

With the "NewCo + RWA + Stablecoin" three-pronged strategy, IVD MEDICAL aims to become: - The "NASDAQ" of medical RWA: monopolizing innovation drug asset tokenization entry points; - The "Visa" of stablecoin payment scenarios: penetrating cross-border payments through IVDD stablecoin; - The "Apple" of Web3 medical ecosystem: integrating technology, assets, and capital into a closed loop.

**V. Epilogue: Challenges After the Madness**

IVD MEDICAL closed July 31st with a market cap of HK$7.84 billion. This enterprise that once sustained itself through IVD distribution now declares in announcements its mission to "make top-tier medical innovation drug IP flow freely like digital currency."

Stablecoin license applications in New York and Hong Kong are still pending, and the NASDAQ listing bell has yet to ring. IVD MEDICAL's "Wild July" resembles a surgical strategic strike — using Web3's scalpel to cut open traditional medical finance vessels, transforming medical innovation drug assets into blockchain "digital gold."

In this summer of innovation drug capital revival, Yongying Fund's Shan Lin's assessment perhaps foreshadows the future: "Innovation drugs remain assets with strong certainty, high confidence, and large space."

IVD MEDICAL's ultimate test lies in whether it can use compliance as a shield to safeguard aggressive innovation, truly opening the door to that $16 trillion RWA market.